C111P: Risankizumab Biosimilar, Human IL-23A (p19) Monoclonal Antibody

Catalog No.: C111P | **Product Name:** Risankizumab Biosimilar, Human IL-23A (p19) Monoclonal Antibody

The research grade Risankizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

PRODUCT SPECIFICATIONS

Catalog No.	C111P
Product Name	Risankizumab Biosimilar, Human IL-23A (p19) Monoclonal Antibody
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	IL-23; IL-23A; IL23 P19; P19; SGRF
Summary	Recombinant Humanized IgG1 kappa Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-human IL-23A (p19) monoclonal antibody risankizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade risankizumab biosimilar specifically binds to the IL-23 alpha protein.
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by risankizumab.
Form Of Antibody	0.2 μM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The Risankizumab Biosimilar, Human IL-23A (p19) Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Risankizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

REFERENCES & BACKGROUND

What is risankizumab biosimilar research grade? Risankizumab (trade name Skyrizi) is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23A). IL-23 is a key cytokine driving the differentiation and maintenance of Th17 cells, which play a central role in the pathogenesis of plaque psoriasis and other immune-mediated diseases. By inhibiting IL-23, risankizumab reduces the production of pro-inflammatory cytokines including IL-17A, IL-17F, and IL-22. Risankizumab is indicated for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, and Crohn’s disease in adults. Risankizumab biosimilar uses the same protein sequences as the therapeutic antibody risankizumab.